Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717896 · ClinicalTrials.gov registry record · Phase 2
Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis
A Phase 2 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT03717896 is a Phase 2 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 102 participants.
The verdict
NCT03717896, a Phase 2 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled trial to determine if administration of intravenous thiamine will lead to quicker resolution of acidosis in patients admitted to the hospital with diabetic ketoacidosis. The investigators will secondarily investigate whether thiamine improves cellular oxygen consumption, shortens intensive care unit (ICU) and hospital stay or decreases hospital resource utilization.
Interventions
- DRUG Placebo
- DRUG 200mg IV thiamine in 50mL 0.9% saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2018-11-21 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03717896
The ClinicalTrials.gov registry entry for NCT03717896 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03717896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03717896 about?
NCT03717896 is a clinical study titled "Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis". This is a randomized, double-blind, placebo-controlled trial to determine if administration of intravenous thiamine will lead to quicker resolution of acidosis in patients admitted to the hospital with diabetic ketoacidosis. The investigators will secondarily investigate whether thiamine improves ce...
What is the current status of trial NCT03717896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2018-11-21. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT03717896?
The interventions under investigation include: Placebo (DRUG), 200mg IV thiamine in 50mL 0.9% saline (DRUG).
Who is sponsoring clinical trial NCT03717896?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.